TITLE

Genentech/Biogen Idec: Rituxan further expands its options

PUB. DATE
April 2006
SOURCE
PharmaWatch: Biotechnology;Apr2006, Vol. 5 Issue 4, p12
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
The article reports that the Rituxan drug developed by Genentech Inc. and Biogen Idec Inc. has gained another approval from the U.S. Food and Drugs Administration (FDA), making it the first selective B-cell therapy to be approved in rheumatoid arthritis in 2006. The FDA approval is for Rituxan in combination with methotrexate for patients with moderately-to-severely active rheumatoid arthritis (RA) who have failed to get adequate relief from at least one of the biologic treatments available.
ACCESSION #
22378393

 

Related Articles

  • Genentech/Biogen Idec: Rituxan further expands its options.  // PharmaWatch: Monthly Review;Apr2006, Vol. 5 Issue 4, p29 

    The article reports that the U.S. Food and Drug Administration approved the drug Rituxan from Genentech Inc. and Biogen Idec Inc. to help treat rheumatoid arthritis (RA). The approval allows the companies to market Rituxan to be used with methotrexate for the treatment of signs and symptoms of...

  • The return of Tysabri to the market in the US?  // Reactions Weekly;3/18/2006, Issue 1093, p3 

    Reports that the U.S. Food and Drug Administration (FDA) Advisory Committee recommended that reintroduction of Tysabri in the U.S. market for the treatment of multiple sclerosis relapse as of March 2006. Details of the Advisory Committee decision; Designation given by the FDA to Tysabri; Plans...

  • Genentech submits sBLA for rheumatoid arthritis drug.  // PharmaWatch: Biotechnology;May2010, Vol. 9 Issue 5, p10 

    The article reports on the submission of a supplemental biologics license application (sBLA) by Genentech Inc. to the Food & Drug Administration (FDA) for Actemra in the U.S. It states that Actemra prevents structural joint damage and improves physical function in adults with active rheumatoid...

  • FDA approves tocilizumab to treat rheumatoid arthritis. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;2/15/2010, Vol. 67 Issue 4, p254 

    The article offers information on the U.S. Food and Drug Administration (FDA) approving the of tocilizumab drug. It reports that the drug treats rheumatoid arthritis and is marketed by Genentech Inc. which made the announcement on January 8. The company said that the drug is first monoclonal...

  • FDA: Complete Response for Rituxan in CLL.  // Bioworld Week;11/23/2009, Vol. 17 Issue 47, p5 

    The article reports on the status of biopharmaceutical firms Genetech Inc. and Biogen Idec Inc.'s drug application approval for Rituxan to treat chronic lymphocytic leukemia (CLL) in the U.S. It mentions that the Food and Drug Administration (FDA) has delayed its decision to approve the drug due...

  • Two New Approvals in Blockbuster Drug Arena. Mirasol, Feliza // Chemical Market Reporter;12/6/2004, Vol. 266 Issue 19, p16 

    This article reports that biotechnology companies Genentech Inc. and Biogen Idec Inc. are dosing the year with good news — early approvals of their two likely products, tarceva and tysabri, formerly referred to as antegren. Last month the U.S. Food and Drug Administration completed its...

  • Medication Adverse Event Reports.  // Fire Engineering;Nov2008, Vol. 161 Issue 11, p44 

    The article reports on medication adverse advice released by the U.S. Food and Drug Administration (FDA). The FDA notes that the use of simvastatin with amiodarone could result to muscle injury, rhabdomyolysis, kidney failure and death. A patient with rheumatoid arthritis who received...

  • Genentech and Biogen Idec obtain FDA complete response for leukemia drug.  // PharmaWatch: Biotechnology;Jan2010, Vol. 9 Issue 1, p17 

    The article reports on U.S. Food and Drug Administration's (FDA) issuance of complete application response for Rituxan plus fludarabine and cyclophosphamide drug for leukemia therapy developed by Genentech Inc. and Biogen Idec Inc. It notes that the applications were based on data from two Phase...

  • Safety summary issued for rituximab.  // Hem/Onc Today;10/10/2008, Vol. 9 Issue 18, p40 

    The article announces that the U.S. Food & Drug Administration MedWatch released a safety summary for rituximab based on an announcement from Genentech and Biogen Idec about the safety of the drug. A long-term safety extension trial revealed that a patient taking rituximab (Rituxan) for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics